报价延迟最少15分钟:2025/07/25 19:06 EDT
盘后时段
|
||||
|
10.12 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.24
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.78/-2.12
|
|
企业价值
328.39M
|
| 资产负债 |
|
每股账面净值
4.32
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/25 19:06 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role. |
